High-Risk DLBCL Beyond R-CHOP

At the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, Lorenzo Falchi, MD, of Memorial Sloan Kettering Cancer Center, discusses emerging frontline strategies for patients with high-risk diffuse large B-cell lymphoma. In this interview, Dr. Falchi explains why standard R-CHOP may be insufficient for certain high-risk populations and outlines the scientific rationale for integrating novel immunotherapies with established chemotherapy backbones. The conversation explores how biologic risk stratification is influencing treatment selection and where frontline innovation may meaningfully improve outcomes. Visit www.bloodcancerstoday.com for more ASH 2025 coverage.